Researchers find CD39 inhibition could be an effective strategy for immunotherapy
Scientists have discovered adenosine could inhibit CD39, a molecule that suppresses the immune system.
List view / Grid view
Scientists have discovered adenosine could inhibit CD39, a molecule that suppresses the immune system.
Researchers have discovered a way to ignite T cells, potentially increasing the scope and success of T cell-based immunotherapy.
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
Researchers have developed a novel microscopy technique to make invisible molecules visible by “de-crowding” to expand a cell or tissue sample before labelling the molecules.
Researchers have found that blocking key enzymes could boost anti-cancer T cell responses and resistance to immunosuppression.
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
Vaccinating mice with this universal flu candidate induced broad neuraminidase inhibition, M2 ectodomain specific antibodies and T cell immune responses.
Researchers have developed a safe and versatile platform to increase the thermal stability of vaccines and improve their transportability.
Researchers have designed a COVID-19 vaccine to be less sensitive to mutations and equipped for future strains.
Scientists have found that unconventional T cells migrate from tissue into the lymph nodes and influence immune responses there.
Researchers have succeeded in developing organoids that contain mature Paneth cells, which were not present in the previous human small intestinal organoids.
The drug candidate, JSF-2659, has been developed to be administered orally, and could be a game changer in treating gonorrhoea.
Researchers have identified latent stem cells that could respond to spinal cord injuries.
The findings by Massachusetts General Hospital could point to a potential target to treat Crohn’s disease.
An animal study has shown that a modified vaccine for tuberculosis could treat bladder cancer whilst minimising side effects.